{"id":"efgartigimod-administration","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reactions"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL4297551","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to FcRn, efgartigimod prevents the recycling of IgG back to the circulation, leading to a decrease in IgG levels. This mechanism is thought to be beneficial in treating autoimmune diseases.","oneSentence":"Efgartigimod is a monoclonal antibody that targets and depletes neonatal Fc receptor (FcRn) to reduce immunoglobulin G (IgG) levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:32.670Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Generalized Myasthenia Gravis"}]},"trialDetails":[{"nctId":"NCT04777734","phase":"","title":"Pre-Approval Access for Efgartigimod PH20 SC in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"AVAILABLE","sponsor":"argenx","startDate":"","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), CIDP","enrollment":""},{"nctId":"NCT06503731","phase":"PHASE2","title":"A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)","status":"RECRUITING","sponsor":"argenx","startDate":"2024-08-30","conditions":"Antibody-mediated Rejection","enrollment":30},{"nctId":"NCT06684847","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome","status":"RECRUITING","sponsor":"argenx","startDate":"2025-01-15","conditions":"Primary Sjogrens Disease","enrollment":580},{"nctId":"NCT07217587","phase":"PHASE3","title":"Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2026-01-05","conditions":"Myasthenia Gravis","enrollment":115},{"nctId":"NCT05701189","phase":"PHASE2","title":"Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome","status":"WITHDRAWN","sponsor":"Chafic Karam","startDate":"2024-09-10","conditions":"Guillain-Barre Syndrome","enrollment":""},{"nctId":"NCT06544499","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia","status":"RECRUITING","sponsor":"argenx","startDate":"2024-10-18","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":69},{"nctId":"NCT07264426","phase":"","title":"Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study","status":"RECRUITING","sponsor":"argenx","startDate":"2025-08-11","conditions":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)","enrollment":200},{"nctId":"NCT07194850","phase":"PHASE2, PHASE3","title":"A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)","status":"RECRUITING","sponsor":"argenx","startDate":"2025-10-20","conditions":"Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia, ITP","enrollment":24},{"nctId":"NCT04833894","phase":"PHASE2, PHASE3","title":"Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis","status":"RECRUITING","sponsor":"argenx","startDate":"2021-10-26","conditions":"Generalized Myasthenia Gravis","enrollment":12},{"nctId":"NCT06637072","phase":"PHASE4","title":"A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC","status":"ACTIVE_NOT_RECRUITING","sponsor":"argenx","startDate":"2024-12-10","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":23},{"nctId":"NCT05374590","phase":"PHASE2, PHASE3","title":"Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis","status":"ENROLLING_BY_INVITATION","sponsor":"argenx","startDate":"2022-08-18","conditions":"Generalized Myasthenia Gravis, gMG","enrollment":12},{"nctId":"NCT04818671","phase":"PHASE3","title":"Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis","status":"COMPLETED","sponsor":"argenx","startDate":"2021-04-26","conditions":"Generalized Myasthenia Gravis","enrollment":184},{"nctId":"NCT04812925","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia","status":"ACTIVE_NOT_RECRUITING","sponsor":"argenx","startDate":"2021-11-17","conditions":"Primary Immune Thrombocytopenia","enrollment":173},{"nctId":"NCT06392386","phase":"PHASE2, PHASE3","title":"A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis","status":"RECRUITING","sponsor":"argenx","startDate":"2024-06-28","conditions":"Generalized Myasthenia Gravis","enrollment":12},{"nctId":"NCT06453694","phase":"PHASE2","title":"Efgartigimod for the Treatment of Acute Optic Neuritis","status":"RECRUITING","sponsor":"Anastasia Vishnevetsky, MD, MPH","startDate":"2025-08-12","conditions":"Optic Neuritis","enrollment":20},{"nctId":"NCT05918978","phase":"PHASE2","title":"Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS","status":"TERMINATED","sponsor":"argenx","startDate":"2023-06-20","conditions":"Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome","enrollment":33},{"nctId":"NCT07072988","phase":"PHASE4","title":"Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2025-09-19","conditions":"Myasthenia Gravis, Generalized","enrollment":50},{"nctId":"NCT06765161","phase":"PHASE3","title":"Efgartigimod in IVIG Dependent Myasthenia Gravis Patients","status":"RECRUITING","sponsor":"Clinique Neuro-Outaouais","startDate":"2025-02-06","conditions":"Myasthaenia Gravis","enrollment":30},{"nctId":"NCT05523167","phase":"PHASE2, PHASE3","title":"A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"argenx","startDate":"2022-10-12","conditions":"Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis","enrollment":265},{"nctId":"NCT06860633","phase":"PHASE4","title":"Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2025-03-06","conditions":"Myasthenia Gravis Crisis, Myasthenia Gravis Exacerbations, AChR Myasthenia Gravis","enrollment":20},{"nctId":"NCT04280718","phase":"PHASE2","title":"A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)","status":"ACTIVE_NOT_RECRUITING","sponsor":"argenx","startDate":"2020-09-18","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","enrollment":229},{"nctId":"NCT07011589","phase":"PHASE1, PHASE2","title":"Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)","status":"NOT_YET_RECRUITING","sponsor":"M. Peter Marinkovich","startDate":"2025-07","conditions":"Epidermolysis Bullosa (EB), Epidermolysis Bullosa Acquisita, Recessive Dystrophic Epidermolysis Bullosa","enrollment":18},{"nctId":"NCT06831058","phase":"PHASE2","title":"A Pilot Study of Efgartigimod for Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2025-05-01","conditions":"Immune-mediated Thrombotic Thrombocytopenic Purpura","enrollment":15},{"nctId":"NCT05633407","phase":"PHASE2","title":"Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS","status":"COMPLETED","sponsor":"argenx","startDate":"2022-09-23","conditions":"Postural Orthostatic Tachycardia Syndrome","enrollment":53},{"nctId":"NCT06885762","phase":"PHASE2, PHASE3","title":"Efgartigimod for the Treatment of Guillain-Barré Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Zhongming Qiu","startDate":"2025-04-13","conditions":"Guillain-Barre Syndrome (GBS)","enrollment":20},{"nctId":"NCT06827587","phase":"NA","title":"Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-02","conditions":"Myasthenia Gravis, Autoimmune Diseases, Neuromuscular Diseases","enrollment":60},{"nctId":"NCT04687072","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia","status":"COMPLETED","sponsor":"argenx","startDate":"2020-12-16","conditions":"Primary Immune Thrombocytopenia","enrollment":207},{"nctId":"NCT06587867","phase":"PHASE3","title":"Seronegative Myasthenia Gravis - Efgartigimod IV","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2023-06-01","conditions":"Efgartigimod, Generalized Myasthenia Gravis","enrollment":30},{"nctId":"NCT02965573","phase":"PHASE2","title":"A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness","status":"COMPLETED","sponsor":"argenx","startDate":"2016-12-30","conditions":"Myasthenia Gravis","enrollment":24},{"nctId":"NCT06502678","phase":"","title":"AUTOANTIBODIES AND SYSTEMIC SCLEROSIS","status":"NOT_YET_RECRUITING","sponsor":"IRCCS Ospedale San Raffaele","startDate":"2024-09-01","conditions":"Understand Pathogenicity of SSc-specific Antibodies in SSc and the Effect of Antibody Blockade in Vitro","enrollment":6},{"nctId":"NCT06497374","phase":"PHASE2","title":"FcRn Antagonists (Efgartigimod) for Acute NMOSD Attack","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2024-07-05","conditions":"Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, NMO Spectrum Disorder","enrollment":63},{"nctId":"NCT03770403","phase":"PHASE3","title":"A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.","status":"COMPLETED","sponsor":"argenx","startDate":"2019-03-01","conditions":"Generalized Myasthenia Gravis","enrollment":151},{"nctId":"NCT04735432","phase":"PHASE3","title":"Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis","status":"COMPLETED","sponsor":"argenx","startDate":"2021-02-05","conditions":"Generalized Myasthenia Gravis","enrollment":110},{"nctId":"NCT03669588","phase":"PHASE3","title":"An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness","status":"COMPLETED","sponsor":"argenx","startDate":"2018-08-22","conditions":"Generalized Myasthenia Gravis","enrollment":167},{"nctId":"NCT03334084","phase":"PHASE1","title":"A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Formulation of ARGX-113 in Healthy Male Subjects","status":"COMPLETED","sponsor":"argenx","startDate":"2017-10-11","conditions":"Bioavailability Study","enrollment":40},{"nctId":"NCT04073589","phase":"PHASE1","title":"Efgartigimod Co-administered Subcutaneously With rHuPH20 in Healthy Subjects","status":"COMPLETED","sponsor":"argenx","startDate":"2019-07-17","conditions":"Healthy Volunteers","enrollment":33}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":50,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vyvgart"],"phase":"phase_3","status":"active","brandName":"efgartigimod administration","genericName":"efgartigimod administration","companyName":"Clinique Neuro-Outaouais","companyId":"clinique-neuro-outaouais","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Efgartigimod is a monoclonal antibody that targets and depletes neonatal Fc receptor (FcRn) to reduce immunoglobulin G (IgG) levels. Used for Generalized Myasthenia Gravis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}